Department of Histology, Embryology and Cytology, Azerbaijan Medical University, Baku, Azerbaijan.
Genetic Resources Institute, Azerbaijan National Academy of Sciences, Baku, Azerbaijan.
J Cancer Res Ther. 2024 Jul 1;20(5):1494-1498. doi: 10.4103/jcrt.jcrt_138_23. Epub 2024 Jan 22.
Pancreatic ductal adenocarcinoma (PDAC) is still a clinical challenge due to its deteriorated prognosis. Therefore, new combination chemotherapeutic approaches are of research interest. In this work, we attempted to characterize the effects of gemcitabine and interferon-alpha as well as the combination of both on the metabolic, pro-apoptotic, and proliferative activity of MiaPaca and Panc-1 cells. We showed that the exposure of both drugs in combination increases effectively the metabolic activity of cells of MiaPaca and Panc-1 cell lines compared to the monotherapies. Based on the data from the analysis of apoptosis, the underlying molecular effect of metabolic and proliferative inhibition is an increase in the number of cells in the early apoptosis. These data can be of interest in the context of future preclinical research.
胰腺导管腺癌 (PDAC) 由于预后较差，仍然是一个临床挑战。因此，新的联合化疗方法是研究的热点。在这项工作中，我们试图描述吉西他滨和干扰素-α以及两者联合应用对 MiaPaca 和 Panc-1 细胞的代谢、促凋亡和增殖活性的影响。我们表明，与单药治疗相比，两种药物联合使用能有效地增加 MiaPaca 和 Panc-1 细胞系的代谢活性。基于凋亡分析的数据，代谢和增殖抑制的潜在分子作用是早期凋亡细胞数量的增加。这些数据在未来的临床前研究中可能具有重要意义。
